This high-profile issue has gained bipartisan attention, but it remains unclear if that’s enough to move it to the finish line. Here’s a review of the current state of play.
The savvy “Right to Desire” campaign relies on feminist messages and social media to raise patient awareness about low libido. Addyi, the only drug currently approved to treat it, has shown limited effectiveness.
During a hearing Tuesday, panel members focused on how drug companies have used patents to allegedly protect their competitive edge and profits.
During Wednesday’s House subcommittee hearing on insulin price hikes, drug makers and benefits managers pointed fingers at each other for the last decade’s 300% price increase, frustrating congressional representatives.
The Senate Finance Committee’s third drug-pricing hearing focused on pharmacy benefit managers, and was more of a fact-finding mission on how these companies operate than a debate about policy proposals.
Though a range of policy solutions have been discussed by Congress, the White House and other experts, a theme of a House subcommittee hearing Tuesday was that providers and insurers are key to correcting the issue.
Clear differences of opinion emerged between Democrats and Republicans during a House Ways and Means subcommittee hearing about how to make prescription drugs more affordable in the Medicare program.
New research shows how an experience with surprise medical bills can guide patients’ future decision-making.
The Centers for Medicare & Medicaid Services launched this month the “What’s Covered” app, designed to provide yes-or-no answers about what services are covered under traditional Medicare. KHN took it for a test drive with real consumers.
Only a small percentage of people who survived an opioid overdose received in the next year some form of drug abuse treatment, according to an analysis of West Virginia Medicaid claims data. Experts say the findings underscore a national disconnect.